Reviewing the Safety of Stopping Heart Medications for Cancer Survivors
Recruiting · Phase 4 · Heart Failure and related conditions · California and Massachusetts
About this trial
This trial looks at how safe it is for cancer survivors to stop taking heart medications when their heart function has returned to normal. Many patients experience heart issues after cancer treatment, and medications help protect their hearts. However, these medications can have side effects and costs. The goal is to see if stopping the medications is safe for patients who no longer need them, with careful monitoring of heart health over time.
The trial's ID number is NCT06183437. It is a Phase 4 trial, meaning it looks at how well stopping medications works and how safe it is. About 335 participants are expected to join, and it is not regulated by the FDA.
Who can join
Adults aged 18 and older who have finished cancer therapy more than 6 months ago and have no plans for further risky treatments. They should have had heart issues related to their cancer therapy that have now improved. Some patients with ongoing heart problems cannot join. The trial team will confirm who is eligible.
Conditions
Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will stop their heart medications under careful supervision. The other group will continue taking their heart medications for at least one year. All participants will have several heart tests to monitor their health over time.
Where
This trial is enrolling at 2 locations. Recruiting sites are listed first.
Brigham and Women's Hospital
Boston, Massachusetts
University of California, Los Angeles
Los Angeles, California